Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Monobenzone→

Monobenzone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
103-16-2
Molecular formula
C13H12O2
Molecular weight
200.2332 g/mol
Drug class
Depigmenting phenolic agentmonobenzyl ether of hydroquinone
Mechanism of action
Causes irreversible depigmentation of melanocytes in treated skin, likely through melanocyte toxicity and interference with melanin synthesis. The mechanism is not fully characterised and the effect is not selective to lesional skin.
Indications / reported uses
  • Historically used to depigment remaining normally pigmented skin in patients with extensive vitiligo when depigmentation of the remaining skin is desired; use is specialist-directed and product authorisation varies by jurisdiction

Sources: NLM MeSH — Monobenzone · PubMed — Monobenzone depigmentation and vitiligo · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Monobenzone Environmental Risk Assessment (ERA) (the Monobenzone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.